Work

A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis

Year: 2015

Type: article

Source: International Journal of Hematology

DOI: 10.1007/s12185-015-1746-8

Authors: Kenji Oritani, Shinichiro Okamoto, Tetsuzo Tauchi, Shigeki Saito, Kohshi Ohishi, Hiroshi Handa, Katsuto Takenaka, Prashanth Gopalakrishna, Taro Amagasaki, Kazuo Ito, Koichi Akashi

Institutions: Osaka University Hospital, The University of Osaka, Keio University Hospital, Tokyo Medical University Hospital, Nagoya University Hospital, Japanese Red Cross Nagoya Daini Hospital, Nagoya University, Mie University, Mie University Hospital, Gunma University, Gunma University Hospital, Kyushu University, Kyushu University Hospital, Novartis (Switzerland), Novartis (Japan), Novartis (United States)

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Novartis, Novartis Pharma, Japan Society for the Promotion of Science

Awards: Targeting cancer stem cells in chronic myeloid neoplasms, Cancer stem cell assay by a new immunodeficient mouse model Cancer stem cell assay by a new immunodeficient mouse model harboring with optimal bone marrow microenvironment

OpenAlex ID: W1977061684

FWCI: 1.469

Cites: 26

Cited by: 12

Related to: 10